Browsing Tag
FGFR2
1 post
HUTCHMED gets priority review for fanregratinib in FGFR2-positive cholangiocarcinoma in China
HUTCHMED’s fanregratinib gains NDA acceptance with priority review in China. Find out what it means for FGFR2-driven cancers and precision oncology adoption.